Xencor, Inc. (XNCR) Stake Raised by Citigroup Inc.

Citigroup Inc. increased its holdings in Xencor, Inc. (NASDAQ:XNCR) by 46.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,693 shares of the biopharmaceutical company’s stock after purchasing an additional 10,007 shares during the period. Citigroup Inc. owned 0.07% of Xencor worth $669,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Alps Advisors Inc. grew its position in shares of Xencor by 0.3% in the second quarter. Alps Advisors Inc. now owns 20,102 shares of the biopharmaceutical company’s stock valued at $424,000 after purchasing an additional 52 shares during the period. Falcon Point Capital LLC grew its position in Xencor by 0.5% during the second quarter. Falcon Point Capital LLC now owns 29,082 shares of the biopharmaceutical company’s stock valued at $614,000 after acquiring an additional 156 shares during the period. Parametric Portfolio Associates LLC grew its position in Xencor by 0.6% during the first quarter. Parametric Portfolio Associates LLC now owns 36,253 shares of the biopharmaceutical company’s stock valued at $867,000 after acquiring an additional 209 shares during the period. Legal & General Group Plc grew its position in Xencor by 4.5% during the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 385 shares during the period. Finally, ProShare Advisors LLC grew its position in Xencor by 4.7% during the second quarter. ProShare Advisors LLC now owns 27,337 shares of the biopharmaceutical company’s stock valued at $577,000 after acquiring an additional 1,226 shares during the period. 76.92% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts have issued reports on XNCR shares. Wedbush reissued an “outperform” rating and set a $29.00 price target on shares of Xencor in a research report on Friday, June 16th. Canaccord Genuity reissued a “buy” rating and set a $36.00 price target on shares of Xencor in a research report on Tuesday, August 8th. Zacks Investment Research downgraded Xencor from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. BidaskClub downgraded Xencor from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Finally, ValuEngine raised Xencor from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $28.00.

In related news, major shareholder John S. Stafford III purchased 41,016 shares of the company’s stock in a transaction dated Tuesday, August 22nd. The shares were acquired at an average cost of $19.69 per share, with a total value of $807,605.04. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder John S. Stafford III purchased 79,035 shares of the company’s stock in a transaction dated Thursday, August 17th. The stock was bought at an average cost of $20.47 per share, for a total transaction of $1,617,846.45. The disclosure for this purchase can be found here. Insiders bought 215,551 shares of company stock worth $4,386,916 over the last ninety days. 4.14% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2017/10/11/xencor-inc-xncr-stake-raised-by-citigroup-inc.html.

Shares of Xencor, Inc. (XNCR) opened at 24.00 on Wednesday. The stock’s market cap is $1.13 billion. Xencor, Inc. has a 52-week low of $18.45 and a 52-week high of $29.38. The firm’s 50-day moving average price is $22.27 and its 200-day moving average price is $22.45.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.10. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%. The business had revenue of $13.34 million for the quarter, compared to the consensus estimate of $8.15 million. On average, equities research analysts forecast that Xencor, Inc. will post ($1.17) earnings per share for the current fiscal year.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

What are top analysts saying about Xencor Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Xencor Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit